Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands by Gout-Zwart, Judith J. et al.
 
 
 University of Groningen
Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2
Diabetes in The Netherlands





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Gout-Zwart, J. J., de Jong, L. A., Saptenno, L., & Postma, M. J. (2020). Budget Impact Analysis of
Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands.
PharmacoEconomics - open, 4(2), 321-330. https://doi.org/10.1007/s41669-019-00179-6
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Vol.:(0123456789)
PharmacoEconomics - Open (2020) 4:321–330 
https://doi.org/10.1007/s41669-019-00179-6
ORIGINAL RESEARCH ARTICLE
Budget Impact Analysis of Metformin Sustained Release 
for the Treatment of Type 2 Diabetes in The Netherlands
Judith J. Gout‑Zwart1,2  · Lisa A. de Jong3 · Lisanne Saptenno3 · Maarten J. Postma3,4,5
Published online: 18 September 2019 
© The Author(s) 2019
Abstract
Background Adverse drug reactions and medication nonadherence are well-known causes of sub-optimal disease control 
and worsened disease outcomes in patients who are treated for type 2 diabetes. Metformin sustained release (SR) might 
reduce these adverse events and improve medication adherence via a simplified treatment regimen for metformin immediate 
release (IR)-intolerant patients.
Objectives The aim of this study is to estimate the budget impact of metformin SR for the treatment of type 2 diabetes in 
the Netherlands, compared to the current standard of care (SoC) with metformin IR.
Methods A budget impact model was built to represent the course of the disease and treatment pathway of type 2 diabetes 
patients eligible for metformin SR from a healthcare payer’s perspective. Patients were considered eligible if they used less 
than 2000 mg metformin IR per day, but suffered from adverse events that might lead to therapy discontinuation, and if they 
were newly diagnosed with type 2 diabetes. The costs of type 2 diabetes treatment and related complications over a time 
horizon of 3 years were calculated. Univariate sensitivity analyses were conducted to show which parameters have the big-
gest influence on the budget impact.
Results The budget impact analysis showed cost-savings of − €1,962,335 over a period of 3 years through implementation of 
metformin SR as an alternative to SoC with metformin IR. Savings were mostly driven by the delay of other, more expensive 
type 2 diabetes treatments, such as insulin. In sensitivity analyses, medication adherence and persistence appeared to have 
the biggest influence on the budget impact.
Conclusion Metformin SR could potentially be a cost-saving alternative to metformin IR for the treatment of type 2 diabetes 
in the Netherlands, especially in patients experiencing adverse events with metformin IR. However, more research is needed 
to better predict the effect of using once-daily metformin, compared to multiple dosages, on medication adherence and per-
sistence and to evaluate whether metformin SR really decreases the amount of adverse events.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4166 9-019-00179 -6) contains 
supplementary material, which is available to authorized users.
 * Judith J. Gout-Zwart 
 judith@ascacademics.com
Extended author information available on the last page of the article
Key Points for Decision Makers 
Using metformin sustained release (SR) might be a cost-
saving alternative to the standard of care with metformin 
immediate release, due to the delay of other, more 
expensive treatments.
Adherence and persistence to metformin SR have a high 
impact on the results of the budget impact analysis.
1 Introduction
The population with type 2 diabetes mellitus is expand-
ing rapidly due to ageing of the population and increased 
obesity. Estimations show an increase from 1.1 million in 
2017 up to 1.3 million patients diagnosed with diabetes 
in 2025 in the Netherlands, out of which 91% will have 
type 2 diabetes [1, 2]. In 2015, the cost of diabetes care 
was approximately €1.6 billion, which was 1.8% of total 
healthcare expenditures.
Diabetes is characterized by a high blood glucose, 
or so called hemoglobin A1c (HbA1c), level of > 7% 
(> 53 mmol/mol). Lowering these levels is of great impor-
tance for controlling the disease. Type 2 diabetes is associ-
ated with severe macro- and microvascular complications, 
such as cardiovascular disease, foot amputations, renal 
disease and visual impairment, especially in patients with 
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poor metabolic control. Sufficient management of diabe-
tes and, therefore, properly controlled HbA1c levels are 
essential for reducing the risk of these complications [3].
Good metabolic control by oral type 2 diabetes treat-
ment could possibly delay other, more invasive treatments, 
like insulin. Treatment with metformin immediate release 
(IR) has proven to be effective in clinical trials; however, 
adverse events (AEs) are a common problem. A Dutch 
study showed that 34.5% of the patients on metformin IR 
experienced AEs, and 11.4–16.1% discontinued their treat-
ment within the first year after initiation [4, 5]. Medica-
tion nonadherence, partially due to (gastrointestinal) AEs 
and difficult treatment regimens, is a well-known problem 
in type 2 diabetes patients [6]. A switch from metformin 
IR to metformin sustained release (SR) might offer an 
improvement in experienced gastrointestinal AEs when 
metformin IR is not tolerated [7–9]. Reducing the amount 
of AEs has the potential to improve medicine compliance 
and adherence, which subsequently might reduce the need 
for other, more expensive antidiabetic drugs and poten-
tially promote better long-term health outcomes [10–12]. 
Also, once-daily dosing may simplify the treatment regi-
men for type 2 diabetes patients and contribute to bet-
ter treatment adherence. Therefore, metformin SR might 
improve glycemic control, ultimately reducing the risk of 
severe diabetes complications and postponing the use of 
other, more expensive antidiabetic drugs.
Various studies have shown therapeutic equivalency or 
even benefit of metformin SR when compared to metformin 
IR, with comparable glycemic control and sometimes a more 
favorable AE profile [7, 10, 11, 13–15]. The economic value, 
however, has not yet been determined. Therefore, the aim of 
this study was to perform a budget impact analysis (BIA) of 
the implementation of metformin SR compared to standard 
of care (SoC) with metformin IR for the treatment of type 2 
diabetes in the Netherlands.
2  Methods
2.1  Model Design
Following the International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) guidelines “Principles of 
Good Practice for Budget Impact Analysis,” a BIA was con-
ducted using a model built in Microsoft Excel 2016 [16, 17]. 
This model evaluated the impact of introducing metformin 
SR, as an alternative to metformin IR, for the treatment of 
type 2 diabetes against a background of other antidiabetics 
(Fig. 1). Several studies showed comparable efficacy and 
safety for metformin SR when compared to metformin IR. 
Most of these studies, however, are considered “switch-
studies,” meaning patients included in the metformin SR 
population have already experienced AEs from metformin 
IR. This leads to bias, which is why AEs were not included 
in this model [7, 10, 11, 13–15].
Figures 2 and 3 show the treatment pathway of patients 
who are treated following SoC, but are eligible for metformin 
SR, over a period of 3 years. Patients in Fig. 2 switched to 
metformin SR, and patients in Fig. 3 keep using metformin 
IR. Within these years, they could either keep using met-
formin or switch to other medications. Besides these met-
formin IR-intolerant patients, 67,249 newly diagnosed type 
2 diabetes patients who initially started metformin SR treat-
ment in year 1 were considered as well (Figs. 4, 5) [18, 19]. 
Guidelines from the Dutch College of General Practitioners 
(Nederlands Huisartsen Genootschap [NHG]) were used to 
outline the treatment pathway of type 2 diabetes patients 
[20]. Persistency was modeled based on a study that assessed 
the transition rates of patients with type 2 diabetes between 
different drugs (classes) (Figs. 2, 3, 4, 5) [21].
Following the ISPOR guidelines, we simulated the 
treatment pathway of each individual patient over a 3-year 
time horizon, based on annual persistence rates per type 
Fig. 1  Flow through of the 
budget impact model. HbA1c 
hemoglobin A1c, IR immediate 
release, OLGD other glucose-
lowering drugs, SR sustained 
release
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2 diabetes drug category. Drug categories taken into con-
sideration were (1) metformin, (2) other glucose-lowering 
drugs (OGLDs: sulphonylurea derivatives, thiazolidine-
diones, alpha-glucosidase inhibitors, glinides, dipeptidyl 
peptidase-4 [DPP-4] inhibitors, glucagon-like peptide-1 
[GLP-1] agonists, sodium-glucose co-transporter-2 
[SGLT-2] inhibitors) and (3) insulin. Following the dis-
tribution of patients through the treatment pathway in the 
model, the possibility of medication (non)adherence was 
assessed and corresponding probabilities of HbA1c goal 
achievement were included [22–24]. Studies in patients 
using metformin SR showed adherence rates ranging 
between 80 and 97.2% [14, 25–27]. In this model, we 
assumed adherence to metformin SR in year 1 as 90%, 
mostly related to the simplified dosing regimen, and adher-
ence to metformin IR was approximately 72%. Although 
the effects of nonadherence on achieved HbA1c have been 
studied for many antidiabetic drugs, the relation is not 
quantified for all glucose-lowering drugs. Using pooled 
data on HbA1c target achievement, the drugs for which 
quantification was missing were graded under one com-
mon denominator: OLGD [24]. Based on the Dutch and 
international guidelines for type 2 diabetes treatment, the 
HbA1c target value was set to ≤ 7% (≤ 53 mmol/mol) [20, 
Fig. 2  Treatment pathway of 
SR eligible type 2 diabetes 
patients currently on SoC who 
are switched to SR [21]. INS 
insulin, OGLD other glucose-
lowering drug, SoC standard of 
care, SR sustained release
Fig. 3  Treatment pathway of SR 
eligible type 2 diabetes patients 
currently on metformin IR who 
stay on IR [21]. INS insulin, 
IR immediate release, OGLD 
other glucose-lowering drug, SR 
sustained release
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28, 29]. Consequently, categories representing “goal” or 
“no goal” were set to HbA1c ≤ 7% (≤ 53 mmol/mol) or 
HbA1c > 7% (> 53 mmol/mol), respectively. Probabilities 
of developing type 2 diabetes related macro- and micro-
vascular complications were linked to the obtained HbA1c 
levels per treatment (Table 1) [30].
The analysis was conducted from a healthcare payers’ 
perspective. The influence of different parameters on the 
budget impact was assessed by univariate sensitivity anal-
yses over a time horizon of 3 years, which was chosen to 
match the payers’ budgeting process [17].
2.2  Study Population
The baseline study population included in the model was 
obtained from Dutch metformin user numbers, as reported 
in the Dutch drug information system of the National 
Health Care Institute (GIPdatabank), and was estimated 
at 640,000 [31]. Patients on metformin IR dosages higher 
than 2000 mg daily were excluded, since switching from 
metformin IR to SR is not recommended when the daily 
dosage of metformin IR is above 2000 mg. Also the maxi-
mum recommended dosage for patients starting metformin 
SR from the start of type 2 diabetes treatment is 2000 mg 
Fig. 4  Treatment pathway of 
newly diagnosed type 2 diabetes 
patients eligible for SR who 
start on SR [21]. INS insulin, 
OGLD oral glucose-lowering 
drug, SR sustained release
Fig. 5  Treatment pathway of 
newly diagnosed type 2 diabetes 
patients eligible for SR who 
start on IR [21]. INS insulin, 
IR immediate release, OGLD 
oral glucose-lowering drug, SR 
sustained release
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[32, 33]. As metformin SR is an alternative to metformin 
IR, we identified which patients would be able to switch 
from SoC to metformin SR and who would continue on 
metformin IR. Factors considered in this respect were (1) 
the discontinuation of metformin IR amongst newly diag-
nosed patients (16.1%), (2) the potential market share of 
metformin SR as calculated from medicine issue registries 
from the United Kingdom (22.53%), and (3) the percent-
age of patients currently on metformin IR who could be 
actively switched to metformin SR (0.1%) [5]. As this BIA 
covers multiple years, type 2 diabetes patient population 
growth was taken into account. This was calculated by the 
number of newly diagnosed patients minus the number of 
deaths, where the number of newly diagnosed patients was 
estimated to be 67,000 by the Dutch healthcare research 
institute NIVEL (2016) [19, 30, 34]. Transition probabili-
ties are displayed in the electronic supplementary material 
(ESM).
2.3  Data Collection
To represent the baseline use of metformin IR as accurately 
as possible, data were collected from three pharmacies rep-
resentative of the Netherlands by pharmatech company Med-
stone [35]. These data were used to determine the average 
cost of metformin use in the Netherlands. The data were 
collected from one pharmacy situated in a city, one in a more 
rural area and one in a small village between August 1, 2017 
and July 31, 2018 and using Anatomical Therapeutic Chemi-
cal (ATC) classification system code A10BA02. Further data 
handling is described in supplementary Fig. 7 (see the “Data 
handling metformin use” section in the ESM). Based on the 
summary of product characteristics (SmPC) recommenda-
tions, patients who used more than 2000 mg metformin 
IR were excluded from the model, leaving information on 
847 prescriptions from unique patients. The obtained data 
included information on the total daily dosage, tablet break-
down and the number of prescriptions (Table 2).
Research has shown the daily dosages of both metformin 
formulations are compatible [36]. To convert the use of met-
formin IR to metformin SR, we assumed that the distribution 
of patients using certain tablet regimens was similar between 
both formulations. However, because metformin IR is avail-
able as 500 mg, 850 mg and 1000 mg and metformin SR as 
500 mg, 750 mg and 1000 mg, some assumptions had to be 
made regarding the daily dosage of metformin SR (Table 3).
2.4  Costs
Costs are shown in Table 4 and the ESM (“Drug cost over-
view” section). Annual drug costs per patient per daily dos-
age (or insulin unit) were calculated using the prescription 
standard for type 2 diabetes from the National Health Care 
Institute (Zorginstituut Nederland [ZIN]) [37, 38]. The 
annual costs of metformin SR are calculated based on the 
assumption of a once-daily treatment regimen. The BIA 
only includes costs as paid by the healthcare payer, there-
fore excluding the patient’s own contribution to the total 
product price. Costs of insulin care and non-insulin care 
were based on information as provided by the Dutch Dia-
betes Foundation (Diabetes Vereniging Nederland) and was 
combined with treatment costs from health insurer declara-
tions [39, 40]. Insulin care consisted of medication, testing 
strips, blood glucose measuring device, blood extraction 
equipment, insulin pens and syringes, remaining diabetes 
tools, an insulin pump and regular checkups/coaching at 
the ophthalmologist or with a diabetes nurse. Non-insulin 
care costs consisted of medication, regular checkups and 
Table 1  Event rates per 1000 person years for sufficient and non-suf-
ficient HbA1c management [30]





All-cause mortality 0.0206 0.0324
(Non)fatal MI 0.0187 0.0317
(Non)fatal stroke 0.0056 0.0081
Amputation/death from peripheral 
vascular disease
0.0012 0.0049
(Non)fatal microvascular disease 0.0079 0.0238
Heart failure 0.0029 0.0053
Cataract extraction 0.0043 0.0065















500 500 1 197 (23.26)
850 850 1 5 (0.59)
1000 1000 1 8 (0.94)
500 2 288 (34.00)
1350 850 1 500 1 1 (0.12)
1500 500 3 103 (12.16)
1000 1 500 1 3 (0.35)
1700 850 2 26 (3.07)
1850 850 1 500 2 1 (0.12)
2000 500 4 120 (14.17)
1000 1 500 2 4 (0.47)
1000 2 91 (10.47)
Total 847 (100)
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coaching by a professional [39, 40]. All costs were inflated 
to the year 2018, using Dutch inflation rates [41]. For the 
BIA, discounting was not applied, as it was our goal to show 
financial streams at each selected budget period and not the 
net present value at the moment of decision-making [17].
3  Results
3.1  Budget Impact Analysis
Over 3 years, the total economic burden of type 2 diabetes 
controlled with metformin IR was €45,723,744. This, com-
pared to the burden of using metformin SR for treatment of 
type 2 diabetes over 3 years, which was €43,761,409, leads 
to cost savings of €1,962,335. No acquisition cost savings 
were seen in year 1, but during the next 2 years, cost sav-
ings substantially increased. Also type 2 diabetes event cost 
savings increased over the years; however, not as strongly 
(Table 5).
3.2  Sensitivity Analysis
In the univariate sensitivity analysis, parameters were var-
ied over a range from 75% to 125%. Out of the 53 variables 
included in the analysis, 15 parameters with the biggest 
influence on the outcome are shown in Fig. 6. The tornado 
diagram shows that not achieving HbA1c targets resulting 
from medication adherence or persistence was most influ-
ential. Low adherence or persistence might make the use of 
metformin SR more costly than metformin IR.
4  Discussion
Several studies have assessed the therapeutic differences 
between metformin IR and metformin SR in an attempt to 
demonstrate metformin SR’s added value [7, 10, 11]. How-
ever, the economic impact of using metformin SR in routine 
clinical practice for the treatment of type 2 diabetes in the 
Netherlands has not yet been quantified.
The results of this BIA show that metformin SR could be 
a cost-saving alternative to metformin IR in the treatment of 
type 2 diabetes. The resulting differences in costs between 
the two formulations are mostly caused by differences in 
acquisition costs. This can be explained by a wide variety in 
metformin treatment regimens amongst the type 2 diabetes 
patient population and the corresponding treatment costs. 
Drug costs included in the model are chosen conservatively, 
always choosing the cheapest treatment option when more 
than one was possible. Furthermore, the metformin SR 
prices included in the model are the upper reimbursement 
limits, as set by the government. To properly reflect the pay-
ers’ perspective, it is necessary to include the drug prices as 
paid by the healthcare payer.
Table 3  Metformin IR versus metformin SR treatment regimens
IR immediate release, SR sustained release











Table 4  Costs included in the budget impact analysis, 2018 price lev-
els
DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, IR 
immediate release, MI myocardial infarction, SGLT-2 sodium-glucose 
co-transporter-2, SR sustained release




Metformin SR 500 mg €21.41 [37]
Metformin SR 750 mg €32.00 [37]
Metformin SR 1000 mg €42.71 [37]
Metformin IR 500 mg €5.23 [37]
Metformin IR 850 mg €8.88 [37]
Metformin IR 1000 mg €10.10 [37]
SGLT-2 inhibitor €579.19 [37]
Sulphonylurea derivatives €25.42 [37]
Thiazolidinediones €13.63 [37]
Alpha-glucosidase inhibitor €230.68 [37]
Glinide €131.04 [37]
DPP-4 inhibitor €493.32 [37]
GLP-1 agonist €1210.03 [37]
Insulin (per unit, IU) €0.03 [37]
Insulin care €456.17 [37]
Non-insulin cost usual care €645.00 [37]
Event costs
(Non)fatal MI €5309 [42]
(Non)fatal stroke €14,280 [42]
Amputation/death from peripheral 
vascular disease
€61,084 [42]
(Non)fatal microvascular disease €94,557 [42]
Heart failure €2966 [42]
Cataract extraction €3054 [42]
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As do all economic analyses, this BIA has its limitations. 
In order to quantify the added economic value of metformin 
SR over metformin IR, several assumptions had to be made. 
Since there was a lack of data on the long-term patient treat-
ment pathways, we simulated the flow of the estimated eli-
gible patient population over all possible drug treatments 
as prescribed following the Dutch treatment guidelines for 
type 2 diabetes, while taking into account the treatment’s 
market share [20, 43]. Future research, where type 2 dia-
betes patients are followed over a longer period of time, 
could provide viable data on treatment pathway utilization 
and the effects of metformin SR on changes in medica-
tion adherence and persistence. These data could validate 
assumptions, decrease uncertainty and increase the models 
predictive strength. Another drawback of the 3-year time 
horizon is that diabetes-related complications often occur 
within 5–10 years or even longer. Because a longer time 
horizon will require a considerable amount of assumptions 
and will therefore increase uncertainty, a long time horizon 
is not recommended [16, 17].
To calculate the cost of metformin SR use, we assumed 
a treatment regimen of one dose per day. This is also 
Table 5  Results budget impact analysis
IR immediate release, MI myocardial infarction, SR sustained release
Metformin IR Metformin SR
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Acquisition cost €2,061,721 €4,096,323 €6,309,202 €2,128,603 €3,997,456 €6,007,782
MI €415,665 €743,836 €1,066,591 €404,490 €723,412 €1,037,354
Stroke €300,786 €537,283 €769,386 €295,099 €526,889 €754,507
Amputation €602,622 €1,086,865 €1,567,360 €565,633 €1,019,258 €1,470,580
Microvascular disease €4,766,415 €8,576,388 €12,346,956 €4,523,268 €8,131,975 €11,710,778
Heart failure €38,104 €68,239 €97,903 €36,952 €66,133 €94,889
Cataract extraction €50,890 €90,941 €130,268 €49,834 €89,011 €127,505
Type 2 diabetes event cost €6,174,482 €11,103,553 €15,978,464 €5,875,277 €10,556,678 €15,195,613
Total cost €8,236,203 €15,199,876 €22,287,666 €8,003,880 €14,554,134 €21,203,395
Budget impact − €232,323 − €645,741 − €1,804,271
Total budget impact − €1,962,335
Fig. 6  Univariate sensitivity analysis. INS insulin, IR immediate release, OGLD other glucose-lowering drug, SR sustained release
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recommended by the manufacturer; however, if glycemic 
control is not satisfying, patients can switch to a dose regi-
men of metformin SR twice daily [32]. We expect this to be 
the case for a small amount of patients, and since it might 
only slightly change the price of the daily dosage, it will 
have a small effect on the outcome as well.
Although several studies have shown therapeutic equiv-
alency between metformin SR and IR, there is also some 
evidence that shows metformin SR to be better tolerated, 
especially when it comes to gastrointestinal side effects [8, 
44]. The savings that can be generated by implementing met-
formin SR could potentially be higher than are presented in 
this model.
The cut-off value for HbA1c is set to 7% (53 mmol/mol) 
to divide the patient population into two groups: proper gly-
cemic control with lowered type 2 diabetes event risks and 
improper glycemic control with an increased risk of type 2 
diabetes events. However, it should be mentioned that this 
cut-off is not applicable to all patient populations, as it can-
not always be a realistic target. Doctors can deviate from 
this value based on a patients age, disease duration and life 
expectancy [20]. Because we calculated the event rates using 
patients with different HbA1c targets, we predict the effect 
on the outcome to be negligible. Also, the predictive value 
of HbA1c for reduction of mortality and complications is 
still up for debate, as it has not been inconclusively proven 
that a reduction of HbA1c results in a reduction of mortality 
or severe macro- and microvascular complications [45, 46].
As diabetes treatments are often added upon one another, 
it might be that the BIA underestimates the potential cost 
savings that could be achieved by the delay of other type 2 
diabetes drugs. Not one drug, but multiple at the same time 
will be postponed. The accumulation of treatments, how-
ever, does not always result in improved disease outcomes. 
Therefore the need for suitable treatments from the start of 
the disease are needed as diabetes is a progressive disease 
which ultimately leads to deteriorating health [47].
5  Conclusion
Our budget impact model shows potential cost savings for 
metformin SR when compared to SoC with metformin IR for 
the treatment of type 2 diabetes in the Netherlands. However, 
to strengthen the model and its outcomes, more research 
on the therapeutic effects and patient-related outcomes of 
metformin SR is needed.
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